TRIPS Agreement — Background, Features, Objectives and Impact on Indian IPR — Intellectual Property Rights II Notes

TRIPS Agreement — Background, Features, Objectives and Impact on Indian IPR

For most of the 20th century, IP was governed by WIPO conventions that had no teeth — a country that ignored them faced no real penalty. The rich, IP-exporting nations were tired of watching their films, drugs and software copied abroad, so in the Uruguay Round (1986–1994) of GATT trade talks they did something clever: they attached IP protection to trade. Break the IP rules now and you could be dragged before the WTO and hit with trade sanctions. That linkage, signed in 1994 and in force from 1 January 1995, is TRIPS — and it is why India rewrote almost its entire IP statute book.

Think of TRIPS as the moment IP law stopped being a gentleman’s agreement and became enforceable trade law. The full name is the Agreement on Trade-Related Aspects of Intellectual Property Rights. It is Annex 1C to the Marrakesh Agreement that established the World Trade Organization (WTO), signed on 15 April 1994 and in force from 1 January 1995. Every country that wants the benefits of WTO membership must accept TRIPS — it is a single undertaking, all or nothing.

A. Background — why TRIPS happened

The older treaties (Paris 1883, Berne 1886) set standards but had no enforcement — a member that flouted them could not be punished.
Developed nations losing money to copying pushed IP into the GATT Uruguay Round so that breaches could be met with trade retaliation.
The result was TRIPS — the most comprehensive international IP agreement, covering copyright, trademarks, geographical indications, industrial designs, patents, layout-designs of integrated circuits and undisclosed information (trade secrets).

B. Salient features

Minimum standards. TRIPS fixes a floor of protection for each kind of IP; members may give more, never less.
National treatment (Art. 3). A member must treat foreigners’ IP no worse than its own nationals’ IP.
Most-favoured-nation, MFN (Art. 4). Any advantage a member gives to the nationals of one country must be given to the nationals of all members — an idea borrowed from trade law and new to IP.
“Berne-plus, Paris-plus”. TRIPS incorporates the substantive provisions of the Paris Convention (Art. 2) and the Berne Convention (Art. 9, except the moral rights of Art. 6bis) and then adds to them.
Patents in all fields (Art. 27). Patents must be available for inventions in all fields of technology, product and process, for a term of 20 years (Art. 33).
Enforcement and dispute settlement. Members must provide effective civil, criminal and border enforcement, and disputes go to the WTO dispute-settlement body (topic 7) — this is the tooth the old treaties lacked.
Transition periods (Arts. 65–66). Developing countries got until 2000 (and for product patents in new areas until 2005) to comply; least-developed countries got longer.

C. Objectives

The stated objects (Art. 7) are to promote technological innovation and the transfer and dissemination of technology, to the mutual advantage of producers and users, in a manner conducive to social and economic welfare. Art. 8 preserves each member’s right to take measures to protect public health and nutrition.

D. Impact on Indian IPR — the statutes that changed

To comply, India overhauled its IP laws:

Patents (Amendment) Acts 1999, 2002 and 2005 — introduced product patents for food, medicines and chemicals from 1 January 2005, a 20-year term, the transitional “mailbox” and Exclusive Marketing Rights.
Trade Marks Act 1999 — replaced the 1958 Act; service marks and well-known marks.
Copyright (Amendment) — brought Indian copyright up to TRIPS/Berne standards.
Designs Act 2000 (Unit IV) and the Geographical Indications of Goods Act 1999.
PPV&FR Act 2001 (Unit III) — India’s sui generis plant-variety law, exercising the option in Art. 27.3(b).
Semiconductor Integrated Circuits Layout-Design Act 2000.

🔑 KEY POINT — India’s most famous TRIPS balance is s.3(d)

TRIPS forced India to grant product patents, but India built in a public-health safeguard — s.3(d) of the Patents Act refuses patents for new forms of known substances that show no enhanced efficacy. The Supreme Court upheld it in Novartis (2013), confirming that India can meet TRIPS and curb “evergreening” of medicines.

Article 27(1), TRIPS: “patents shall be available for any inventions, whether products or processes, in all fields of technology, provided that they are new, involve an inventive step and are capable of industrial application … patents shall be available and patent rights enjoyable without discrimination as to the place of invention, the field of technology and whether products are imported or locally produced.”

In Simple Terms: TRIPS is the WTO’s IP rulebook (in force 1995). It sets a minimum level of protection for every kind of IP, demands national treatment and MFN, absorbs Paris and Berne, requires 20-year patents in all fields, and — crucially — backs it all with WTO trade sanctions. India obeyed by rewriting its patent, trademark, copyright, design, GI and plant-variety laws between 1999 and 2005.

🧩 WORKED EXAMPLE — must India patent a “new form” of an old drug?

Facts. A foreign company holds a patent on a cancer drug and seeks an Indian patent for a new salt form of the same molecule, arguing TRIPS Art. 27 requires India to grant it.

Rule. Art. 27 requires patents for inventions that are new, inventive and industrially applicable — but TRIPS leaves each member to define patentability and preserves public-health flexibilities (Art. 8). India’s s.3(d) refuses new forms of known substances lacking enhanced efficacy.

Apply. The salt form is a new form of a known substance; unless it shows a significant improvement in therapeutic efficacy, s.3(d) bars it, and this is TRIPS-compatible because TRIPS sets a floor, not a ceiling.

Decoy. “Art. 27 says all fields” does not mean every application must be granted — novelty, inventive step and each member’s genuine patentability standards still apply.

Conclusion. India may refuse the patent under s.3(d) without breaching TRIPS — exactly what Novartis (2013) decided.

flowchart TD
    ROOT["TRIPS Agreement (WTO Annex 1C, in force 1995)"]:::root
    ROOT --> A["Minimum standards for all IP"]:::leaf
    ROOT --> B["National treatment + MFN (Arts. 3, 4)"]:::leaf
    ROOT --> C["Incorporates Paris + Berne (Berne-plus)"]:::leaf
    ROOT --> D["20-year patents in all fields (Arts. 27, 33)"]:::leaf
    ROOT --> E["WTO dispute settlement + sanctions"]:::leaf
    ROOT --> F["Indian impact: Patents 2005, TM 1999, Designs 2000, GI 1999, PPV&FR 2001"]:::impact
    classDef root fill:#FFF8DC,stroke:#000,stroke-width:1px,color:#000;
    classDef leaf fill:#E6F3FF,stroke:#1E3A8A,color:#000;
    classDef impact fill:#E8F5E9,stroke:#1B5E20,color:#000;
    linkStyle default stroke:#888,stroke-width:1px;

Case Laws

[C-6] Novartis AG v Union of India (2013) — s.3(d) is TRIPS-compatible; India may refuse “evergreening” patents while honouring TRIPS.
Bayer Corporation v Union of India (2014) — India’s first compulsory licence (for the drug Nexavar) upheld; TRIPS flexibilities in action.

📄 Full notes + Question Bank (₹199) — every topic in depth, model answers to all past KSLU questions, in one printable PDF. Get the bundle · 10 Solved Problems · All Intellectual Property Rights II topics